Navigation Links
CWRU School of Medicine has evidence vaccine against malaria will reduce disease
Date:12/20/2007

CLEVELAND December 20, 2007 Researchers at the Case Western Reserve University School of Medicines Center for Global Health & Diseases published data potentially impacting the three billion people exposed to malaria every year. Brian T. Grimberg, Ph.D., Peter A. Zimmerman, Ph. D., and Christopher L. King, M.D., Ph.D. published in the December issue of Public Library of Science Medicine (PLoS Medicine), novel findings proving new antibodies inhibit infection by the Plasmodium vivax (P. vivax) malaria parasite. The research suggests a Duffy binding protein-based vaccine could provide protection against malaria blood-stage infection. This specific protein is an attractive candidate for a P. vivax vaccine, as it could decrease illness in malaria prevalent regions. For the first time, scientists from the eight partner institutions along with the Center for Global Health & Diseases, conclusively proved that invasion of human red blood cells by the malaria parasite could be prevented by these antibodies.

Unlike other types of malaria, a P. vivax infection relies solely upon the single molecular interaction between the Duffy antigen on human red blood cells and the Duffy binding protein expressed by the parasite to establish the disease. By interrupting the interaction of parasite binding to the red cell, the researchers and their colleagues around the United States and in Papua New Guinea, India, and Thailand, have the potential to eliminate P. vivax malaria. By exploiting this required interaction, the research offers a clear path toward development of a P. vivax malaria vaccine.

James W. Kazura, M.D., Director of the Center for Global Health and Diseases at Case Western Reserve University emphasized P. vivax is widely distributed throughout Asia, the South Pacific, parts of Africa, and South America. However, the importance of developing a P. vivax vaccine to the American public is underscored by the fact that this is the form of malaria most frequently transmitted in Afghanistan, Iraq, and adjoining regions where United States troops are currently stationed.

For more than 50 years the Case Western Reserve School of Medicine has dedicated significant effort to the field of international health. This emphasis was initiated by the late Frederick C. Robbins, M.D., Dean of the School of Medicine from 1966 to 1980, and Nobel Laureate for discovering methods that led to development of the polio vaccine.

Malaria, deemed one of the worlds big three diseases, along with tuberculosis and HIV/AIDS, kills one million people every year. There are currently 70 million cases of P. vivax worldwide. The diseases prevalence has increased in recent years through the worldwide spread of drug resistance, which is why a vaccine is desperately needed. This Case Western Reserve University School of Medicine research is particularly encouraging because it offers one of the first feasible vaccine concepts for the most common form of malaria.


'/>"/>

Contact: Jessica Studeny
jessica.studeny@case.edu
216-368-4692
Case Western Reserve University
Source:Eurekalert

Related biology news :

1. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
2. Rutgers high school outreach gets $3 million boost from NSF
3. UGA Odum School of Ecology professor receives grant to study West Nile Virus in NYC
4. Folic acid lowers blood arsenic levels, according to Mailman School of Public Health study
5. UMass Medical School researchers receive $8.5M grant award to fight AIDS
6. Asthma link to post-traumatic stress disorder, says Mailman School of Public Health study
7. Kids eat more fruits, vegetables when schools offer salad bar
8. New research seeks to enhance quality and security of wireless telemedicine
9. Penn Veterinary Medicine report new strategy to create genetically-modified animals
10. SNM applauds NAS study showing need to restore federal nuclear medicine research funding
11. Gene-targeting pioneer Mario Capecchi shares 2007 Nobel Prize in Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... 2016  The American College of Medical Genetics and Genomics ... as one of the fastest-growing trade shows during the ... Bellagio in Las Vegas . ... growth in each of the following categories: net square feet ... of attendees. The 2015 ACMG Annual Meeting was ranked 23 ...
(Date:6/20/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring announced that ... has secured the final acceptance by all three ... Access Systems (MAS) installed. Furthermore, Securus will have ... installed by October, 2016. MAS distinguishes between legitimate ...
(Date:6/9/2016)... -- Paris Police Prefecture ... to ensure the safety of people and operations in several ... tournament Teleste, an international technology group specialised in ... that its video security solution will be utilised by ... safety across the country. The system roll-out is scheduled for ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published ... how a patient who developed lymphedema after being treated for breast cancer benefitted from ... the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
Breaking Biology Technology: